MiPT
MiPT (N-methyl-N-isopropyltryptamine) is a synthetic tryptamine described by Shulgin, reported to produce predominantly cognitive and emotional effects with comparatively few visuals. It is used non-medically. Human data are anecdotal; potency and safety are uncharacterised, with wide individual dose variation.
01 Overview
MiPT is a non-hydroxylated, non-methoxylated tryptamine. User reports describe an effect that is more mental and emotional than visual, sometimes characterised as a psychedelic with a clear headspace and limited perceptual distortion.
No controlled human studies exist. All information is anecdotal, so dose ranges are approximate and vary between individuals. Serotonergic side effects and psychological distress are possible, particularly at higher doses.
02 Mechanism
Serotonin 5-HT2A receptor agonist (classical psychedelic mechanism) with activity at additional serotonin subtypes.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 10–20 mg | Oral | Approximate; from user reports. |
| Common | 20–40 mg | Oral | Onset ~30-60 min, duration ~4-6 h. Not clinically validated. |
| Strong | 40–60 mg | Oral | Higher risk of overwhelming effects. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Cognitive and emotional effectsPredominantly mental and emotional alteration with introspective quality. | Anecdotal | ||
| Mild visual effectsVisuals reported to be modest relative to 4-hydroxy tryptamines. | Anecdotal | ||
| Mood elevationEuphoria and emotional openness reported at moderate doses. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| NauseaGastrointestinal discomfort during onset. | Mild | Common | Anecdotal | |
| Cardiovascular stimulationIncreased heart rate and blood pressure. | Mild | Common | Anecdotal | |
| Anxiety / psychological distressAnxiety or confusion, more likely at high doses or in poor setting. | Moderate | Common at higher doses | Anecdotal |